Medtronic (XSWX:MDT) ROCE %: 9.83% (As of Apr. 2026)


XSWX:MDT Medtronic PLC XSWX:MDT
21 GF Score
Price CHF65.29
GF Value CHF80.97
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Medtronic ROCE %?

Medtronic XSWX:MDT +1.21% 21 ROCE % is 9.83% as of Apr. 2026. GuruFocus rates XSWX:MDT with a GF Score™ of 21/100 and a GF Value™ of CHF80.97 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medtronic's annualized ROCE % for the quarter that ended in Apr. 2026 was 9.83%.

Medtronic  (XSWX:MDT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medtronic ROCE % Related Terms

Medtronic ROCE % Historical Data

* Premium members only.

The historical data trend for Medtronic's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medtronic ROCE % Chart

Medtronic Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.54 7.29 6.94 7.69 8.32

Medtronic Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.31 8.84 7.72 9.83
XSWX:MDT
21GF Score
Medtronic PLC XSWX:MDT
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medtronic ROCE % Calculation

Medtronic's annualized ROCE % for the fiscal year that ended in Apr. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Apr. 2026 )  (A: Apr. 2025 )(A: Apr. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Apr. 2026 )  (A: Apr. 2025 )(A: Apr. 2026 )
=5395.848/( ( (76433.616 - 10737.222) + (73268.853 - 9181.841) )/ 2 )
=5395.848/( (65696.394+64087.012)/ 2 )
=5395.848/64891.703
=8.32 %

Medtronic's ROCE % of for the quarter that ended in Apr. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Apr. 2026 )  (Q: Jan. 2026 )(Q: Apr. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Apr. 2026 )  (Q: Jan. 2026 )(Q: Apr. 2026 )
=6332.304/( ( (72218.259 - 7495.353) + (73268.853 - 9181.841) )/ 2 )
=6332.304/( ( 64722.906 + 64087.012 )/ 2 )
=6332.304/64404.959
=9.83 %

(1) Note: The EBIT data used here is four times the quarterly (Apr. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 9.83% mean?
Medtronic (XSWX:MDT) has a ROCE % of 9.83% as of Apr. 2026.
Is Medtronic's ROCE % too high?
Medtronic's current ROCE % is 9.83%. The Medical Devices & Instruments industry median ROCE % is 2.23. Medtronic's value of 9.83% is 340.8% above this industry median. Overall, Medtronic has a GF Score™ of 21/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medtronic's ROCE % compare to SYK and BSX?
Medtronic's ROCE % of 9.83% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Medtronic's value of 9.83% is 340.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medtronic's current ROCE % of 9.83% is 340.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medtronic's current ROCE % is 9.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtronic stock overvalued right now?
Based on GuruFocus' analysis, Medtronic (XSWX:MDT) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF80.97, compared to a current price of CHF65.29 — trading 19.4% below its estimated fair value. The current ROCE % is 9.83% and 340.8% above the Medical Devices & Instruments industry median of 2.23. Medtronic's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Medtronic (XSWX:MDT), the current ROCE % is 9.83% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medtronic (XSWX:MDT) Overvalued in 2026?

Based on GuruFocus' analysis, Medtronic stock appears to be undervalued. The current stock price of CHF65.29 is trading 19.4% below its estimated GF Value™ of CHF80.97. GuruFocus considers Medtronic to be Modestly Undervalued.

Key valuation signals for XSWX:MDT:

  • ROCE %: 9.83%
  • GF Value™: CHF80.97 vs. price of CHF65.29 (19.4% below fair value)
  • GF Score™: 21/100 with 3 warning signs
  • Industry Position: 340.8% above the Medical Devices & Instruments median

No single metric tells the full story. See the XSWX:MDT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medtronic Business Description

Address Parkmore Business Park West, Building Two, Galway, IRL
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
21GF Score

Get the complete analysis for XSWX:MDT

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF65.29
Price
CHF80.97
GF Value